about
Current challenges and novel treatment strategies in double hit lymphomasBoth leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyThe BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism.Persistent complement-dependent anti-AnWj in a lymphoproliferative disorder: a case study and review.Targeting BCL2 for the treatment of lymphoid malignancies.Transformed Lymphoma.BH3 mimetic therapy: an emerging and promising approach to treating chronic lymphocytic leukemia.Venous thromboembolism management practices and knowledge of guidelines: a survey of Australian haematologists and respiratory physicians.Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax.BCL2 inhibition in double hit lymphoma.Charcot-Leyden crystalsAcquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic LeukemiaStructures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutationsDynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
P50
Q26770385-8FB295A2-D08E-40AF-9447-7E93A6C400FFQ33412553-444566CA-CBF7-45F4-90D7-F9E899EEC3E4Q33438428-5096BFD0-FE4E-4B62-9108-ED4DA2D111E3Q37035832-80ACCC6A-DD77-4477-9057-E33D7B6633DAQ37998474-4A4D43D1-094F-4987-A1C1-BE35A74A3FC6Q38232485-B6922935-A7AD-42AE-9454-25474CD9EC26Q39020656-8EC79153-A7C4-4E93-AA97-7F856414C6F4Q43445440-B0DE1A23-38AD-4084-9F6C-0FFB5D5197C8Q47768399-76F34AF3-9F7C-4CB5-9F5A-20C5EAB3A06EQ48189581-EF8C177F-1BFA-4119-9107-4EE96D0563B3Q53003244-198CA775-9688-4C6D-96D2-75E928386309Q82872509-8CCEBDCD-F8CB-4088-BE5C-D85BC692B11BQ90258038-34D055B6-EC79-4B98-BF77-E83F5639E080Q92501889-91D60A30-0A74-47B6-A8F0-F12FB61E61FDQ93223071-B4B69E2E-8570-4B13-96A1-9298123350B8
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
M A Anderson
@en
M A Anderson
@nl
type
label
M A Anderson
@en
M A Anderson
@nl
prefLabel
M A Anderson
@en
M A Anderson
@nl
P108
P31
P496
0000-0002-3515-0215